Monday, May 27, 2019

T1 bright cortical lesions in context of PML

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426496/

Hyperintense cortical signal (HCS) in pre-contrast T1-weighted images on MRI has been described in a variety of CNS conditions and most notably in hypoxia/ischemia, status epilepticus, hypoglycemia, osmotic demyelination syndrome, and mitochondrial disorders. Less frequent associations have been made with immunologic disorders such as systemic lupus erythematousus or subacute sclerosing panencephalitis, and meningoencephalitis.

MRI T1 bright lesions according to content and location

Table 1


Table 2

Wednesday, March 20, 2019

Colistin

Dosing: Adult
Note: Dosage expressed in terms of mg of colistin base activity (CBA). CBA 1 mg is defined to be equivalent to colistimethate sodium (CMS) 30,000 units which is equivalent to ~2.4 mg CMS (see table below) (EMA 2014; Falagas 2006; Kassamali 2013; Nation 2014; Nation 2017).
Colistimethate Sodium Conversion (EMA 2014)
Colistimethate Sodium
Colistimethate Sodium
Colistin-Base Activity (CBA)
12,500 units
1 mg
0.4 mg
150,000 units
12 mg
5 mg
1,000,000 units
80 mg
34 mg
4,500,000 units
360 mg
150 mg
9,000,000 units
720 mg
300 mg

Susceptible infections: IM, IV: 2.5 to 5 mg CBA/kg/day in 2 to 4 divided doses; maximum: 5 mg CBA/kg/day
Severe infections (due to multidrug-resistant organisms susceptible to colistin in the critically ill) (off-label dosing): IV: Loading dose: 300 mg CBA followed by 150 mg CBA twice daily (Dalfino 2012; Plachouras 2009). Additional trials may be necessary to further evaluate the use of this dosing in critically ill patients with this condition.
May also consider using the following calculations; however, although derived from critically ill patients, the use of this algorithm has not been prospectively evaluated in the critically ill. Attainment rates for the desirable target colistin concentration (2 mg/L) using these calculations in patients with creatinine clearance ≥80 mL/minute were ~40%; consider combination therapy with other antibacterials for these patients, especially for treatment of respiratory tract infection and/or for organisms with colistin MIC ≥1 mg/L (Nation 2017):
Loading dose of colistin base activity (mg) = Target average colistin steady-state plasma concentration (in mg/L) x 2 x weight (in kg). For patient weight, use the lower of ideal or actual body weight expressed in kg. Application of these equations has not been evaluated in obese patients.
Daily maintenance dose of colistin base activity (mg) = Target average colistin steady-state plasma concentration (in mg/L) x 10(0.0048 x CrCl [mL/minute] + 1.825) in 2 divided doses. Administer twice daily beginning 12 hours after loading dose. See Dosing: Renal Impairment: Adult for frequency of administration based on CrCl.
Note: Do not exceed a loading dose of 300 mg CBA or a total daily dose of 360 mg CBA due to risk of nephrotoxicity (according to this algorithm). Target Css,avg is typically 2 mg/L and should be based on MIC, site, and severity of infection. CrCl is expressed in mL/minute (Nation 2016; Nation 2017).
Bronchiectasis, pulmonary colonization/infection with susceptible organisms in cystic fibrosis and noncystic fibrosis patients (off-label use/route): Inhalation: 30 to 150 mg CBA via nebulizer 1 to 2 times daily (maximum dose: 150 mg CBA 2 times daily) (Haworth 2014; Le 2010; Sabuda 2008; Steinfort 2007). Note: An optimal dosing regimen has not been determined and varies widely among studies; lower doses have been used in noncystic fibrosis patients with bronchiectasis (Steinfort 2007).
Cystic fibrosis (off-label use): IV: 3 mg CBA/kg/day in 3 divided doses (Young 2013)
Meningitis and ventriculitis (susceptible gram-negative organisms; adjunct to systemic therapy) (use a preservative-free preparation): Intrathecal/intraventricular (off-label route): 4.2 mg CBA/day (equivalent to 10 mg CMS/day) (IDSA [Tunkel 2017]; Imberti 2012; Ziaka 2013); Note:Dose in clinical reports has ranged from 0.7 to 8.3 mg CBA/day in 1 or 2 divided doses (administered with concomitant systemic antimicrobial therapy) (Benifla 2004; De Bonis 2016; Falagas 2007; Fotakopoulos 2016; Imberti 2012; Katragkou 2005; Rodríguez Guardado 2008). When intraventricular colistimethate is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF) (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]). Intraventricular administration is generally reserved for use in patients who fail parenteral therapy despite removal of CSF shunt or when CSF shunt cannot be removed (Baddour 2018).
Pneumonia, hospital-acquired or ventilator-associated due to susceptible multidrug-resistant gram-negative bacilli (eg, Pseudomonas aeruginosaAcinetobacter spp) (off-label):
Nebulization (via ventilator circuit): 150 mg CBA every 8 hours delivered over 60 minutes for 14 days or until successful wean from mechanical ventilation (treatment duration range: 7 to 19 days) (Lu 2012). May consider using as an adjunct in patients receiving IV colistin; may improve clinical outcomes (Doshi 2013; Tumbarello 2013; Valachis 2015).
IV: Loading dose: Target average colistin steady-state plasma concentration (in mg/L) x 2 x weight (in kg); use the lower of ideal or actual body weight, followed by a maintenance dose beginning 12 hours after the loading dose; the daily maintenance dose (in mg) may be calculated with the following equation: Target average colistin steady-state plasma concentration (in mg/L) x 10(0.0048 x CrCl [mL/minute] + 1.825) and administered in 2 divided doses every 12 hours based on CrCl (see Dosing: Renal Impairment: Adult) (Nation 2017). Caution is advised when administering loading doses >300 mg CBA or daily doses >360 mg CBA. Attainment rates for the desirable target colistin concentration (2 mg/L) using these calculations in patients with creatinine clearance ≥80 mL/minute were ~40%; consider combination therapy with other antibacterials for these patients with CrCl ≥80 mL/minute especially for organisms with colistin MIC ≥1 mg/L (Nation 2017). Also consider using adjunctive inhaled colistin. When used for empiric treatment of ventilator-associated pneumonia, use in combination with an agent with MRSA activity (or MSSA activity, if appropriate), with or without an additional antipseudomonal agent (dependent on risk factors) (IDSA [Kalil 2016]).
Administration: Adult

Parenteral: Administer by IM, direct IV injection over 3 to 5 minutes, intermittent infusion over 30 minutes (Beringer 2001; Conway, 1997), or by continuous IV infusion (according to the manufacturer). For continuous IV infusion, one-half of the total daily dose is administered by direct IV injection over 3 to 5 minutes followed 1 to 2 hours later by the remaining one-half of the total daily dose diluted in a compatible IV solution infused over 22 to 23 hours. The final concentration for continuous infusion administration should be based on the patient's fluid needs; infusion should be completed within 24 hours of preparation.

Inhalation (off-label route): Administer solution via nebulizer (vibrating plate nebulizer may be preferred [Lu 2012]) promptly following preparation to decrease possibility of high concentrations of colistin from forming which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010). If patient is on a ventilator, place medicine in a T-piece at the midinspiratory circuit of the ventilator. One study in adult patients with VAP administered colistimethate over 60 minutes using a vibrating plate nebulizer positioned on the inspiratory limb 10 cm proximal to the Y-piece (Lu 2012).

Note: A case report of fatal lung toxicity implicated in vitro colistin formation from an inhalation solution as a potential etiology, but data regarding the concentration, formulation and storage of the inhaled colistin administered to the patient were not reported (FDA 2007; McCoy 2007; Wallace 2008). An acceptable limit of in vitro colistin formation to prevent potential toxicity is unknown. Limited stability data are available regarding the storage of colistin solution for inhaled administration (Healan 2012; Wallace 2008). Storing for >24 hours may increase the risk for potential lung toxicity; preparation immediately prior to administration is recommended (FDA 2007; Le 2010, Wallace 2008).

Intrathecal/intraventricular (off-label route): Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow colistimethate solution to equilibrate in the CSF (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).


Friday, October 19, 2018

Velum interpositum

https://radiopaedia.org/articles/velum-interpositum

The velum interpositum is a small membrane containing a potential space just above and anterior to the pineal gland which can become enlarged to form a cavum velum interpositum.

Gross anatomy
The velum interpositum is formed by an invagination of pia mater forming a triangular membrane the apex of which points anteriorly.

Boundaries
superiorly: the columns of the fornices and hippocampal commissure (psalterium) reaching as far forward as the foramen of Monro
inferiorly: the internal cerebral veins and tela choroidea of the third ventricle
inferolaterally: the thalamus
posteriorly: the narrow base of the triangle abuts the splenium of the corpus callosum 1

It varies in shape from persion to person, sometimes interposed between the internal cerebral veins and splenium, and depending on whether or not there is a cavum vergae (in which case the columns of the fornices are displaced inferiorly, narrowing the velum interpositum).

When somewhat distended by fluid it forms a small triangular (in axial section) space and is referred to as a cavum velum interpositum. If larger and exterting mass effect it is known as a cavum velum interpositum cyst.

Image result for velum interpositum

Normal values for serum albumin in pregnancy


https://academic.oup.com/tropej/article/28/4/193/1695011


https://www.ncbi.nlm.nih.gov/pubmed/7507040
Early Hum Dev. 1993 Oct;34(3):209-15.
Albumin levels in pregnancy: a hypothesis--decreased levels of albumin are related to increased levels of alpha-fetoprotein.

Maher JE1, Goldenberg RL, Tamura T, Cliver SP, Hoffman HJ, Davis RO, Boots L.
Department of Obstetrics and Gynecology, University of Alabama at Birmingham 35233-7333.

Abstract
Serum albumin levels decrease during pregnancy while the concentration of most other maternal serum proteins of hepatic origin remain stable or increase. In a study of 289 women, most maternal characteristics such as race, age, smoking, a history of previous low birth-weight, infant sex and gestational age at delivery were not related to maternal serum albumin levels at 18 or 30 weeks' gestational age. The degree of maternal obesity significantly correlated with the concentration of albumin. There was a significant negative correlation in individual women between maternal serum levels of albumin and alpha-fetoprotein, with high levels of maternal serum alpha-fetoprotein predicting lower levels of albumin. We hypothesize that there may be a negative feedback effect of alpha-fetoprotein of fetal origin on the maternal production of albumin during pregnancy.
PMID: 7507040

Sunday, September 16, 2018

Pathergy (Uptodate)

Pathergy refers to an erythematous papular or pustular response to local skin injury. It is defined as a pustule-like lesion or papule that appears 48 hours after skin prick by a 20-gauge needle. Pathergy is less common in North American and North European patients with Behçet syndrome (10 to 20 percent) than in patients from more endemic areas (50 to 75 percent) [32]. Dermographism is a response to light scratching of the skin that may be present in some patients [33]. A vascular pathergy-like response may be evident after vascular procedures, resulting in phlebitis or aneurysms [34,35]. Reference 32-35 is 1-4.

  1. Assar S, Sadeghi B, Davatchi F, et al. The association of pathergy reaction and active clinical presentations of Behçet's disease. Reumatologia 2017; 55:79.
  2. Dinç A, Karaayvaz M, Caliskaner AZ, et al. Dermographism and atopy in patients with Behçet's disease. J Investig Allergol Clin Immunol 2000; 10:368.
  3. Lê Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol 1995; 22:2103.
  4. O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 1990; 16:423.

Sunday, August 26, 2018

Valproate reduces stroke risk?

Stroke 2018; 49: 54-61
Brooke's RL et al, from the Stroke Research Group
Histone deacetylase inhibitor
Variant of a histone deacetylase gene is associated with large artery stroke (HDAC9)
Sodium Valproate is a non specific inhibitor of HDAC9

Saturday, July 29, 2017

FSHD inheritance

 2012 Mar;131(3):325-40. doi: 10.1007/s00439-011-1100-z. Epub 2011 Oct 9.

Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?



Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy after the dystrophinopathies and myotonic dystrophy and is associated with a typical pattern of muscle weakness. Most patients with FSHD carry a large deletion in the polymorphic D4Z4 macrosatellite repeat array at 4q35 and present with 1-10 repeats whereas non-affected individuals possess 11-150 repeats. An almost identical repeat array is present at 10q26 and the high sequence identity between these two arrays can cause difficulties in molecular diagnosis. Each 3.3-kb D4Z4 unit contains a DUX4 (double homeobox 4) gene that, among others, is activated upon contraction of the 4q35 repeat array due to the induction of chromatin remodelling of the 4qter region. A number of 4q subtelomeric sequence variants are now recognised, although FSHD only occurs in association with three 'permissive' haplotypes, each of which is associated with a polyadenylation signal located immediately distal of the last D4Z4 unit. The resulting poly-A tail appears to stabilise DUX4 mRNAs transcribed from this most distal D4Z4 unit in FSHD muscle cells. Synthesis of both the DUX4 transcripts and protein in FSHD muscle cells induces significant cell toxicity. DUX4 is a transcription factor that may target several genes which results in a deregulation cascade which inhibits myogenesis, sensitises cells to oxidative stress and induces muscle atrophy, thus recapitulating many of the key molecular features of FSHD.


Wednesday, March 22, 2017

Hypoglycorrhachia

The maintenance of CSF glucose levels is controlled by several mechanisms, including glucose transport into and out of the CSF as well as glucose utilization by cells. Glucose enters the CSF through the blood-brain barrier at the choroid plexus with the help of glucose transport proteins (such as GLUT1) and can either be used by cells or exit through the arachnoid villi into the venous system 119. The pathophysiology behind hypoglycorrhachia is not fully understood but is likely multifactorial. Possible contributors include decreased glucose delivery to the choroid plexus because of reduced blood flow, decreased transport across the blood-brain barrier, increased metabolism in the brain, and increased glucose transport out of the CSF into the venous system 1. While it was once thought that an increased rate of glycolysis by bacterial or immune cells was the primary cause of hypoglycorrhachia, this is no longer conventional thought12021

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065645/#__ffn_sectitle

Friday, January 13, 2017

When was the term SRSE first used?

Super-refractory status epilepticus is defined as status epilepticus that continues or recurs 24 h or more after the onset of anaesthetic therapy, including those cases that recur on the reduction or withdrawal of anaesthesia. It was a term used first in the Third London-Innsbruck Colloquium on status epilepticus held in Oxford on 7–9th April 2011 (Shorvon and Trinka, 2011)
Shorvon SD, Trinka E. Proceedings of the 3rd London-Innsbruck Colloquium on Status Epilepticus. Epilepsia 2011;52 Suppl 5.

Tuesday, December 6, 2016

EEG patterns of status

CONVULSIVE PATTERNS

Primary generalized tonic-clonic status epilepticus
Electrographically, the seizures characteristically begin with a flattening of the normal background rhythms, followed by generalized low voltage fast activity or polyspikes that increase in amplitude and decrease in frequency until these patterns become obscured by muscle and movement artifact. As the seizure clinically moves into the clonic phase, the EEG characteristically shows a checkerboard type pattern of muscle artifact corresponding to the rhythmic jerking movements observed clinically. During breaks between seizures, the EEG shows diffuse suppression of cerebral activity.

Generalized myoclonic status epilepticus
The EEG in myoclonic status epilepticus may show generalized, bisynchronous polyspikes, spikes, or sharp waves preceding and time-locked with the clinical myoclonus, superimposed on a diffusely slow and suppressed background. A burst-suppression pattern may also be seen. Of note, due to the accompanying muscle activity associated with the myoclonic movements, discerning true epileptiform activity from muscle artifact can often be challenging. In this case, the use of a short-acting paralytic agent may aid in determining if the myoclonus is cortically generated or whether it originates lower down the neuro-axis (ie, brainstem, spinal cord, or peripheral site). Ultimately, this determination may be difficult without simultaneous EEG and electromyography (EMG) with jerk-locked back-averaging techniques.

Generalized clonic status epilepticus
The EEG typically shows generalized, synchronous spikes or spike wave complexes time-locked with the clinical movements.

Generalized tonic status epilepticus
Tonic seizures have a propensity to cluster and are more common during non–rapid eye movement (REM) sleep. The electrographic appearance of tonic seizures consists of moderate to high amplitude, frontally predominant, generalized 10-25 Hz spikes, sometimes termed generalized paroxysmal fast activity (GPFA). A second ictal tonic EEG pattern consists of an abrupt, generalized attenuation or flattening of the background EEG activity (to < 5-10 µV) that can be the sole manifestation of the ictal activity or can precede the development of the 10-25 Hz generalized spikes.

Generalized atonic status epilepticus
Atonic seizures are common in patients with Lennox-Gastaut syndrome and are a prominent feature in patients with myoclonic-astatic epilepsy of Doose. The ictal EEG during atonic seizures typically shows either generalized polyspike-and-wave or generalized slow-spike-and-wave (SWS) activity, followed by diffuse, high-amplitude, generalized slow waves maximal over the central head regions.

Simple partial status epilepticus
The ictal EEG in simple partial status epilepticus may show any of a range of patterns from focal spikes, polyspikes, spike and waves, suppression, or focal rhythmic discharges of any frequency to a completely normal background without evidence of ictal activity. Because approximately 6 cm2 of synchronously firing cortex must be involved for EEG to detect ictal activity, it should not be surprising that many focal seizures will be beyond the resolution of scalp EEG, because the ictal focus is too small, too distant, or unfavorably oriented in relation to the electrodes (ie, originating deep in a sulcus) to be detected by scalp recording.

In such instances when the focal seizures cannot be detected by scalp recording, functional imaging modalities such as cerebral positron emission tomography (PET)—which measures cerebral glucose metabolism—or single photon emission computed tomography (SPECT) scanning—which measures regional cerebral blood flow—may be helpful in confirming the diagnosis. If such studies are performed during ongoing clinical signs or symptoms, increased local glucose metabolism or regional cerebral blood flow would verify the suspected seizure focus.

Complex partial status epilepticus
Because a significant amount of cortex (ie, >6 cm2) is typically involved to produce impaired consciousness, complex partial seizures will have an ictal correlate on EEG. The ictal footprint is variable and may consist of focal spikes, polyspikes, spike waves, suppression, or focal rhythmic discharges of any frequency.

NONCONVULSIVE PATTERNS

Typical absence status epilepticus
The classic EEG finding in typical absence status epilepticus is generalized 3 Hz spike-and-wave activity (range 2.5-4 Hz). However, generalized polyspike-and-wave may also be seen. The intradischarge frequency is classically constant but may vary over the course of the seizure.

Atypical absence status epilepticus
In contrast to typical absence seizures, in atypical absences, the onsets and offsets are clinically less abrupt and distinct and the seizures are longer in duration (lasting up to minutes). Additionally, changes in tone are more prominent than in typical absence seizures. The ictal EEG shows slow (< 2.5 Hz) generalized spike-and-wave complexes that may be more irregular and asymmetric than what is classically seen in typical absence status epilepticus.

Nonconvulsive SE with Partial Onset

Primary criteria
An electrographic or nonconvulsive seizure may be demonstrated by any electrographic pattern lasting at least 10 seconds and satisfying any 1 of the following 3 primary criteria:
*Repetitive generalized or focal spikes, sharp-waves, spike-and-wave, or sharp-and-slow wave complexes at a frequency of 3 or more per second.
*Repetitive generalized or focal spikes, sharp-waves, spike-and-wave, or sharp-and-slow wave complexes at a frequency of 3 or less per second AND one of the secondary criteria below.
*Sequential rhythmic, periodic, or quasi-periodic waves at 1 or more per second and unequivocal evolution in: (1) frequency (increasing or decreasing by at least 1/sec), (2) morphology, or (3) location. Of note, evolution in amplitude alone is not sufficient to meet the criteria for evolution. Additionally, change in sharpness of the waveform without other change in morphology is also not adequate to qualify as evolution of morphology.

Secondary criteria
An electrographic or nonconvulsive seizure may be additionally demonstrated by significant improvement in the patient’s clinical state or the appearance of previously-absent normal EEG patterns (such as a posterior dominant rhythm or sleep transients) temporally coupled to the acute administration of a rapidly-acting antiepileptic drug such as a benzodiazepine. Of note, resolution of the suspected ictal pattern without clinical improvement or the appearance of previously absent normal EEG patterns would not satisfy the secondary criteria.
When rhythmic, periodic, or quasi-periodic electrographic patterns fail to fulfill these criteria in an obtunded or comatose patient who lacks other clinical signs of seizure activity, the diagnosis of nonconvulsive status epilepticus becomes more difficult and controversial. Patterns such as lateralized periodic discharges (LPDs, formerly termed PLEDs); bilateral, independent periodic discharges (BIPDs, formerly termed BIPLEDs); generalized periodic discharges (GPDs, formerly termed GPEDs); and stimulus-induced rhythmic, periodic, or ictal discharges (SIRPIDs) represent ambiguous but potentially ictal patterns whose clinical significance and management remain controversial topics.

From 

Wednesday, June 22, 2016

Dose of Lacosamide

Dosing: Adult (Uptodate)
Partial onset seizure:
Monotherapy: Oral, IV:
Initial: 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.
Alternative initial dosage: Loading dose: 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. Note: Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.
Maintenance: 150 to 200 mg twice daily. Note: For patients already on a single antiepileptic and converting to lacosamide monotherapy, maintain the maintenance dose for 3 days before beginning withdrawal of the concomitant antiepileptic drug. Gradually taper the concomitant antiepileptic drug over ≥6 weeks.
Adjunctive therapy: Oral, IV:
Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.
Alternative initial dosage: Loading dose of 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. Note: Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.
Maintenance dose: 100 to 200 mg twice daily (maximum: 400 mg daily)
Status epilepticus, refractory (off-label use): IV: 200 to 400 mg followed by a daily maintenance dose of 200 to 600 mg daily in 2 divided doses (Albers, 2011; Goodwin, 2011; Kellinghaus, 2011; NCS [Brophy, 2012]). Note: Although the Neurocritical Care Society recommends administration of the initial dose at a rate of 200 mg over 15 minutes, others have administered doses of up to 400 mg IV push over ≤5 minutes without apparent harm (Goodwin, 2011; Kellinghaus, 2011; NCS [Brophy, 2012]).

How do seizures stop? A review

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738747/

This is an interesting article from Fred Lado and Solomon Moshe, which reviews literature on mechanisms for seizure termination.


How does a status epilepticus become super refractory?

http://brain.oxfordjournals.org/content/134/10/2802

This question is obviously crucial to successful management. It is a common clinical experience that the more severe the precipitating insult (for instance, in status epilepticus after trauma infection or stroke), the more likely is the status epilepticus to become super-refractory. However, super-refractory status epilepticus also occurs frequently in previously healthy patients without obvious cause.
In all these cases, the processes that normally terminate seizures have proved insufficient (for review, see Lado and Moshe, 2008). At a cellular level, one of the most interesting recent discoveries has been the recognition that receptors on the surface of axons are in a highly dynamic state, moving onto (externalization), away from (internalization) and along the axonal membrane. This ‘receptor trafficking’ intensifies during status epilepticus, and the overall effect is a reduction in the number of functional γ-aminobutyric acid (GABA) receptors in the cells affected in the seizure discharge (Arancibia and Kittler, 2009; Smith and Kittler, 2010). As GABA is the principle inhibitory transmitter, this reduction in GABAergic activity may be an important reason for seizures to become persistent. Furthermore, the number of glutaminergic receptors at the cell surface increases, and the reduction in the density of the GABA receptors is itself triggered it seems by activation of the glutaminergic receptor systems. Why this should happen is unknown, and from the epilepsy point of view is certainly maladaptive. This loss of GABAergic receptor density is also the likely reason for the increasing ineffectiveness of GABAergic drugs (such as benzodiazepines or barbiturates) in controlling seizures as the status epilepticus becomes prolonged (Macdonald and Kapur, 1999). It has also been repeatedly shown that the extracellular ionic environment, which can change in status epilepticus, may be an important factor in perpetuating seizures, and the normally inhibitory GABA(A)-mediated currents may become excitatory with changes in extracellular chloride concentrations (Lamsa and Taira, 2003).
Other cellular events might also be important. Mitochondrial failure or insufficiency may be one reason for the failure of seizure termination and cellular damage and mitochondrial processes are involved in cell necrosis and apoptosis (Cock et al., 2002). Another category of disease triggering persistent status epilepticus is inflammatory disease (Tan et al., 2010), and inflammatory processes may be important in the persistence of status epilepticus. The opening of the blood–brain barrier almost certainly plays a major role in the perpetuation of seizures, due to a variety of possible mechanisms (Friedman and Dingledine, 2011), and this may be especially the case in status epilepticus due to inflammation (Marchi et al., 2011). This may explain the benefits of steroids in the therapy of status epilepticus. Leakage of the blood–brain barrier will also lead to higher potassium levels and excitation (David et al., 2009). No genetic mechanism has been identified to explain the failure of seizure termination although massive changes in gene expression occur within minutes of the onset of status epilepticus.
At a systems level, it has been suggested rather fascinatingly and counter intuitively that status epilepticus results from a failure to synchronize seizure activity (Schindler et al., 2007a, b; Walker, 2011), and that the lack of synchrony somehow prevents seizure termination.
These mechanisms influence strategies for therapy. However, often overriding is the importance of establishing cause of the status epilepticus, for emergency therapy directed at the cause may be crucial in terminating the episode (for review of the influence of aetiology on prognosis, see Neligan and Shorvon, 2011).

Tuesday, January 12, 2016

Joint position and vibration sense in the cord

http://www.ncbi.nlm.nih.gov/pubmed/2926427

Hankey GJ, Edis RHThe utility of testing tactile perception of direction of scratch as a sensitive clinical sign of posterior column dysfunction in spinal cord disorders. J Neurol Neurosurg Psychiatry. 1989 Mar; 52(3): 395-8.

Classical beliefs about the functions of the dorsal columns of the spinal cord have been attacked following recent evidence that position and vibration sensations may be carried in the dorsal spinocerebellar tracts. There is evidence that the one specific function of the dorsal columns is for the transmission of information concerning the direction of tactile cutaneous movement. Thirty normal controls, 43 patients with spinal cord disorders and 10 patients with functional disorders were examined prospectively using an easily administered "direction of scratch" protocol. Interpretation of the direction of a 2 cm vertical tactile cutaneous movement over the lower limbs was found to be accurate in normal controls and grossly inaccurate in patients with functional disorders, exceeding the error rate of guessing. Detection of direction of 2 cm scratch was moderately impaired in 11 of 13 patients with spastic paraparesis and preserved sensation to all other modalities and 23 of 24 patients with spastic paraparesis and impaired proprioception and/or vibration sensations. Direction of 2 cm scratch, proprioception and vibration sensations were preserved in the three cases with anterior spinal cord syndromes. It is proposed that tactile perception of direction of 2 cm scratch over the lower limbs is a sensitive sign of posterior column function which can be usefully incorporated into the clinical sensory examination in the evaluation of spinal cord disorders.